121 results about "Clindamycin" patented technology

A pharmaceutical composition containing clindamycin and benzoyl peroxide is disclosed for the treatment of acne. The composition is stable for several months when stored at room temperature. Methods of preparing and of using the composition are disclosed.

A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively comprising clindamycin or a pharmaceutically acceptable salt or ester thereof, and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection.

The present invention provides a remedy for sarcoidosis, one of systemic granulomatous diseases, and a method for treating sarcoidosis. A remedy for sarcoidosis containing a Propionibacterium acnes-targeting antibiotic such as minocycline hydrochloride and clindamycin as an active component is prepared. Further, sarcoidosis is treated by administering this remedy for sarcoidosis to sarcoidosis patients.

The invention relates to a novel pharmaceutical combination comprising clindamycin and clotrimazole for use for vaginal infections.

The present invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of misoprostol and an effective amount of an antibiotic. A suitable antibiotic is selected from the group consisting of doxycycline, gentamicin, tobramicin, ciprofloxacin, clindamycin, clarithromycin, azithromycin and metronidazole. Preferred antibiotics are doxycycline and ciprofloxacin. More preferably, the antibiotic is doxycycline. In its second aspect, the present invention is directed to a method for treating periodontal disease in a mammalian patient comprising administering to a mammalian patient in need of such treatment a therapeutically effective amount of misoprostol and an effective amount of an antibiotic. Typically, the mammalian patient is a human.

A Bacillus strain characterized by (i): sensitivity for ampicillin, vancomycin, gentamicin, kanamycin, streptomycin, erythromycin, clindamycin, tetracycline and chloramphenicol; (ii) antimicrobial activity against E. coli and Clostridium perfringens; and (iii) a sporulation percentage of at least 80 when measured after 2 days of incubation. The invention further relates to a method for selecting such strains. Many of the identified strains according to the invention are of the species Bacillus amyloliquefaciens. Some of the Bacillus amyloliquefaciens were further identified as Bacillus amyloliquefaciens subsp. amyloliquefaciens whereas others were identified as amyloliquefaciens subsp. plantarum. A Bacillus strain of the invention may be used as a feed additive to animal feed where it has a probiotic effect.

The invention discloses a medical composite alginate dressing containing antibacterial drugs and a preparation method thereof. In parts by weight, the medical composite alginate dressing comprises the following components: 50-99.9 parts of alginate and 0.05-10 parts of antibacterial drugs, The antibacterial drug is selected from gentamicin or its salt, neomycin or its salt, amikacin or its salt, fusidic acid or its salt, kanamycin or its salt, polycresol , mupirocin, sulfamethonium or its salt and clindamycin or its salt at least one. The medical composite alginate dressing of the present invention has strong ability to absorb exudate, has good water vapor transmission rate, can be biodegraded and has good biocompatibility, does not adhere to the wound and can quickly form gel after absorbing wound exudate , has strong moisturizing properties, can effectively promote wound healing, shorten wound repair time, can effectively prevent or treat sensitive bacterial infections, and can be widely used in acute and chronic wounds with exudate.

The vagina effervescent tablet has the salt or ester of clindamycin and metronidazole as active component and is prepared via a common tablet making process. The present invention features that the said effervescent tablet contains hydroxypropyl methyl cellulose as adhesive. Compared with conventional effervescent tablet, the present invention has the advantages of greater foam amount, fine and lasting foams, homogeneous distribution of effective medicine component, long duration, raised medicine curative effect, simple preparation process, stable quality and being suitable for industrial production.

Disclosed is an ointment using the salts or esters of clindamycinum and metronidazole as the active constituents, the constituents of the ointment include (by weight percent): clindamycinum or its medicinal salts or its esters 0.25-5%, metronidazole 0.2-4%, oleaginous base 10-40%, water soluble base 5-50%, and balancing water, wherein the oleaginous base is selected from stearinic acid, glyceryl monostearate, paraffin wax, fluid wax, Vaseline, lanoline, cetyl alcohol, stearyl alcohol, Span series, bee wax, animal or vegetable fat, the water soluble base is selected from glycerin, propylene glycol, sorbitol, polyethylene glycol series, Tween series, sodium dodecylsulfate, dimethyl sulfoxide, triethanolamine, and ethanol.

The invention relates to an ointment and a preparation method thereof, in particular to an acne ointment and a preparation method thereof. The acne ointment comprises a morning ointment and an evening ointment. The morning ointment comprises a first ingredient and a corresponding substrate, and the evening ointment comprises a second material and a corresponding substrate. The first material comprises 2% of nicotinamide, 1% of ortho-hydroxybenzoic acid, 1% of clindamycin, 1.5% of oil soluble azone and 0.2% of Nepal methyl ester. The second material comprises 10% of anchoic acid, 0.1% of Adapalene, 1% of clindamycin, 1% of salicylic acid, 1.5% of grease azone and 0.2% of Nepal methyl ester. The ointment has the advantages of having easily sourced material, being non-toxic and safe, having good therapeutic effects and being simple in preparation.

The invention provides an impurity analysis preparation method for clindamycin. The method is used for analyzing clindamycin materials and separating and preparing impurities from the materials, and comprises the following steps of: (a) measuring the clindamycin materials by an LC-MS (Liquid Chromatography-Mass Spectrometry) method, and determining one or more impurities in the materials according to the relative retention time and / or the molecular weight of the analyzed component; (b) determining the conditions of a column chromatography method according to the relative retention time and / or the molecular weight of one or more impurities, and gathering one or more impurities corresponding to the relative retention time and / or the molecular weight by the normal phase silica gel column chromatography method; and (c) determining the conditions of a preparative chromatography method according to the chromatographic retention behavior displayed by the relative retention time of one or more impurities in the step (a), and collecting one or more impurities corresponding to the retention time by the preparative chromatography method.

Compositions for topical application for treating a skin disorder (e.g., acne) include a retinoid, which is solubilized completely in alcohol only with the aid of cosolvents such as esters (e.g., alkyl benzoate, isopropyl palmitate, isopropyl myristate, diisopropyl adipate and their derivatives). This completely solubilized retinoid can be used to formulate an emulsion system or liquid to powder suspension containing a second active, such as an antibiotic (e.g., clindamycin).

The invention provides a polypeptide having the molecular weight of 3321.6 Da and having an amino acid sequence as shown in SEQ ID NO.1. The invention also provides six derivatives of the polypeptide. The polypeptide and the derivatives thereof provided by the invention have efficient broad-spectrum bacteriostatic effect on gram positive bacteria and gram negative bacteria (especially having good killing effect on anti-clindamycin anaerobic propionibacterium acnes), fungi and yeasts, and have high activity (the concentration for killing the propionibacterium acnes in vitro can be only 0.125 mg / L). The polypeptide and the derivatives thereof can be applied in preparation of microbial bacterial and fungal infection-controlling and anti-inflammatory products, wherein the products include externally-applied disinfectants, anti-bacterial agents, wound-protection or infection-prevention dressings, acne treating drugs, skin care products, cosmetics and the like. The polypeptide is designed and synthesized based on a tryptophan bromide-containing fragment of a marine biological sea urchin, has stronger bacteria inhibiting or killing and anti-inflammatory effects and better stability, and can be used as an antibiotic substitute.

The invention relates to an industrial production method for producing clindamycin or the salts of clindamycin. The method uses dual-trichloromethyl carbonate or trichloromethyl methyl chloroformate and amide to prepare the intermediate chlorophthalic agent. The method of the invention has high product purity, high yield, easier post-processing and other technical advantages, compared with the prior art.

The invention provides an analysis method for detecting the clindamycin in cosmetic by use of high efficiency liquid chromatograph, and the invention is characterized in that octadecylsilane chemically bonded silica is adopted as the C18 column or the C8 column of filler, and an ultraviolet detector or a diode array detector are used to detect at the position of 190 to 380 nm; the mobile phase adopts ammonium dihydrogen phosphate solution-acetonitrile buffer solution or ammonium dihydrogen phosphate solution-methanol buffer solution; the sample is dissolved and extracted by dried methyl alcohol or acetonitrile, and, after extracted by ultrasound for 20 minutes, is centrifuged in 12000rpm / min for around 5 minutes. The clear liquid is the sample liquid, which is, if necessary, filtered by 0.45Mu meters filtering membrane for preparation; the qualitative analysis is conducted according to the sample retention time and the spectrogram, and the quantitative analysis is conducted according to the peak area. The invention has the advantages of high solution and sensitivity, and perfect reproducibility and selectivity as well as simple sample pre-treating method, thereby being applicable to microanalysis of clindamycin in cosmetic.

The invention discloses an integrated treatment process of clindamycin alkaline wastewater and belongs to the technical field of wastewater treatment. The process includes steps of: subjecting the clindamycin alkaline wastewater produced in a certain workshop section to Fe2<2+> / K2S2O8 oxidation pretreatment, and feeding the wastewater into a two-stage separation internal circulation anaerobic reactor and a multi-stage A / O reactor to perform biological treatment. The process integrates advantages of a Fe2<2+> / K2S2O8 oxidation technology, the two-stage separation internal circulation anaerobic reactor and the multi-stage A / O reactor. After treatment, the COD removal rate of the wastewater can be more than 99%, the ammonium-nitrogen removal rate can be more than 95%, and the total nitrogen removal rate can be more than 90%. In addition, a biogas product with economic value can be produced. The integrated process has characteristics of small agent adding amounts, high resistance to impact load, low system running costs, stable running, and the like.

Compositions for topical application for treating a skin disorder (e.g., acne) include a retinoid, which is solubilized completely in alcohol only with the aid of cosolvents such as esters (e.g., alkyl benzoate, isopropyl palmitate, isopropyl myristate, diisopropyl adipate and their derivatives). This completely solubilized retinoid can be used to formulate an emulsion system or liquid to powder suspension containing a second active, such as an antibiotic (e.g., clindamycin) or benzoyl peroxide.

A kit comprising a soap-free cleanser and a topical composition which comprises clindamycin or a pharmaceutically acceptable salt or ester thereof, and a pharmaceutically acceptable carrier, formulations and packages thereof, and methods of using the same to treat various skin disorders.

A highly storage-stable composition for vaginal administration of clindamycin is disclosed which is useful for the treatment of bacterial vaginosis. The composition is a vaginal suppository containing an antimicrobially effective amount of clindamycin dispersed in a Hard Fat NF suppository base. Hard Fat NF suppository bases provide a clindamycin product having long term storage stability while providing efficacy against bacterial vaginosis which is equivalent to clindamycin vaginal creams.

The invention relates to the technical field of drugs for skin diseases, in particular to acne cream and a preparing method thereof. The acne cream is made from terbinafine hydrochloride, rifampicin, clindamycin, borneol, puerarin powder, poria cocos powder and dandelion. By means of compatibility of medicines contained in the acne cream, the acne cream can comprehensively treat pathomycete, bacteria and viruses which cause acne in the view of Western medicine and heat, poison and dampness which cause acne in the view of traditional Chinese medicine, treatment effect is thorough and remarkable, and patients who have acne can be cured comprehensively at low cost within a short period of time so as to return to normal life. Furthermore, the preparing method of the acne cream enables the treatment effect of the acne cream to be guaranteed, operation is easy, production cost is low, and the acne cream is convenient to carry and take.

The invention relates to the biotechnical field, in particular to primers and a method for rapidly identifying group B streptococcus and detecting drug resistance thereof and primer application. Four pairs of specific primers are as follows: a cfb gene primer pair cfb-F and cfb-R for identifying the group B streptococcus; an ermB gene primer pair ermB-F and ermB-R for detecting the drug resistance of the group B streptococcus to macrocyclic lactones; an mefA / E gene primer pair mefA / E-F and mefA / E-R for detecting the drug resistance of the group B streptococcus to macrocyclic lactones; an linB gene primer pair linB-F and linB-R for detecting the drug resistance of the group B streptococcus to lincosamides. The method comprises the following steps: Step 1, DNA extraction; Step 2, primer design; Step 3, gene amplification; Step 4, result interpretation. According to the invention, the primers can identify GBS (group B streptococcus) in a genital tract of a pregnant woman and detect the drug resistanceof the GBS to erythromycin and clindamycin at the same time so as to guide clinical medication.

This document relates to methods and materials for reducing the risk of infection after a shoulder surgery or medical procedure. For example, this document relates to methods and materials for using a topical composition containing clindamycin or erythromycin to reduce the risk of or to prevent infection associated with shoulder surgeries or medical procedures.

The present invention provides for a topical dermatological composition that includes diclofenac and clindamycin, in a pharmaceutically acceptable medium, wherein at least one of the diclofenac and clindamycin is at least partially microencapsulated.

The invention describes an antibiotic coating for porous bodies and its use. Into the porous system of non-metallic porous bodies and of metallic porous bodies, a coating made of at least one antibiotic salt that is hardly soluble in water or in an aqueous environment from the group of the netilmicin laurate, the netilmicin myristate, the netilmicin dodecyl sulfate, the sisomicin laurate, the sisomicin myristate, the sisomicin dodecyl sulfate, the gentamicin laurate, the gentamicin myristate, the clindamycin laurate, the amikacin laurate, the amikacin myristate, the amikacin dodecyl sulfate, the kanamycin laurate, the kanamycin myristate, the kanamycin dodecyl sulfate, the tobramycin laurate, the tobramycin myristate, the tobramycin dodecyl sulfate, the ciprofloxacin myristate, the vancomycin dodecyl sulfate, the vancomycin laurate, the vancomycin myristate, the vancomycin teicoplanin and the clindamycin teicoplanin is introduced. The antibiotically coated, porous bodies are used as implants.